glp 1 drugs ingredients GLP-1 Support Handout: Illegal ingredients linked to
Description
Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.
A closer look at how GLP-1 medications may impact fertility, PCOS, and reproductive health.
The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022
The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157
